161 related articles for article (PubMed ID: 8895542)
21. Differential regulations of matrix metalloproteinases and tissue inhibitors of metalloproteinases in dermal fibroblasts by dibutyril cyclic AMP.
Kuroda K; Shinkai H
J Dermatol Sci; 1997 Aug; 15(2):95-100. PubMed ID: 9279690
[TBL] [Abstract][Full Text] [Related]
22. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines.
Afzal S; Lalani el-N ; Foulkes WD; Boyce B; Tickle S; Cardillo MR; Baker T; Pignatelli M; Stamp GW
Lab Invest; 1996 Feb; 74(2):406-21. PubMed ID: 8780160
[TBL] [Abstract][Full Text] [Related]
23. Matrix metalloproteinases and TIMPS in cultured C57BL/6J-cpk kidney tubules.
Rankin CA; Suzuki K; Itoh Y; Ziemer DM; Grantham JJ; Calvet JP; Nagase H
Kidney Int; 1996 Sep; 50(3):835-44. PubMed ID: 8872958
[TBL] [Abstract][Full Text] [Related]
24. Effect of phorbol ester and cytokines on matrix metalloproteinase and tissue inhibitor of metalloproteinase expression in tumor and normal cell lines.
Mackay AR; Ballin M; Pelina MD; Farina AR; Nason AM; Hartzler JL; Thorgeirsson UP
Invasion Metastasis; 1992; 12(3-4):168-84. PubMed ID: 1284126
[TBL] [Abstract][Full Text] [Related]
25. Resistance of malignant trophoblast cells to both the anti-proliferative and anti-invasive effects of transforming growth factor-beta.
Graham CH; Connelly I; MacDougall JR; Kerbel RS; Stetler-Stevenson WG; Lala PK
Exp Cell Res; 1994 Sep; 214(1):93-9. PubMed ID: 8082752
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine).
Velders AH; Bergamo A; Alessio E; Zangrando E; Haasnoot JG; Casarsa C; Cocchietto M; Zorzet S; Sava G
J Med Chem; 2004 Feb; 47(5):1110-21. PubMed ID: 14971891
[TBL] [Abstract][Full Text] [Related]
27. The distribution of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal cancer.
Gallegos NC; Smales C; Savage FJ; Hembry RM; Boulos PB
Surg Oncol; 1995; 4(2):111-9. PubMed ID: 7551259
[TBL] [Abstract][Full Text] [Related]
28. Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors.
Lampert K; Machein U; Machein MR; Conca W; Peter HH; Volk B
Am J Pathol; 1998 Aug; 153(2):429-37. PubMed ID: 9708803
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the effects of the antimetastatic compound ImH[trans-RuCl4(DMSO)Im] (NAMI-A) on the arthritic rat and on MCa mammary carcinoma in mice.
Sava G; Gagliardi R; Cocchietto M; Clerici K; Capozzi I; Marrella M; Alessio E; Mestroni G; Milanino R
Pathol Oncol Res; 1998; 4(1):30-6. PubMed ID: 9555118
[TBL] [Abstract][Full Text] [Related]
30. Inter-regulated balance between gelatinases and tissue inhibitor (TIMP-1) in isolated human glomeruli.
Zaoui P; Barro C; Maynard C; Descotes JL; Maurizi-Balzan J; Cordonnier DJ; Morel F
Ren Fail; 1998 Mar; 20(2):201-9. PubMed ID: 9574444
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma.
Prontera C; Mariani B; Rossi C; Poggi A; Rotilio D
Int J Cancer; 1999 May; 81(5):761-6. PubMed ID: 10328230
[TBL] [Abstract][Full Text] [Related]
32. Lipodermatosclerosis is characterized by elevated expression and activation of matrix metalloproteinases: implications for venous ulcer formation.
Herouy Y; May AE; Pornschlegel G; Stetter C; Grenz H; Preissner KT; Schöpf E; Norgauer J; Vanscheidt W
J Invest Dermatol; 1998 Nov; 111(5):822-7. PubMed ID: 9804345
[TBL] [Abstract][Full Text] [Related]
33. MMP and TIMP expression pattern in pleural effusions of different origins.
Eickelberg O; Sommerfeld CO; Wyser C; Tamm M; Reichenberger F; Bardin PG; Solèr M; Roth M; Perruchoud AP
Am J Respir Crit Care Med; 1997 Dec; 156(6):1987-92. PubMed ID: 9412584
[TBL] [Abstract][Full Text] [Related]
34. Effects of the Ru(III) complexes [mer-RuCl3(DMSO)2Im]degrees and Na[trans-RuCl4(DMSO)Im] on solid mouse tumors.
Sava G; Pacor S; Mestroni G; Alessio E
Anticancer Drugs; 1992 Feb; 3(1):25-31. PubMed ID: 1623212
[TBL] [Abstract][Full Text] [Related]
35. Expression of type IV collagen and its degrading enzymes in squamous cell carcinoma of lung.
Nakagawa H; Yagihashi S
Jpn J Cancer Res; 1994 Sep; 85(9):934-8. PubMed ID: 7961122
[TBL] [Abstract][Full Text] [Related]
36. Antimetastatic action and toxicity on healthy tissues of Na[trans-RuCl4(DMSO)Im] in the mouse.
Gagliardi R; Sava G; Pacor S; Mestroni G; Alessio E
Clin Exp Metastasis; 1994 Mar; 12(2):93-100. PubMed ID: 8306532
[TBL] [Abstract][Full Text] [Related]
37. Differential regulation of glomerular gelatinase B (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in obese Zucker rats.
Schaefer L; Han X; August C; Matzkies F; Lorenz T; Schaefer RM
Diabetologia; 1997 Sep; 40(9):1035-43. PubMed ID: 9300240
[TBL] [Abstract][Full Text] [Related]
38. Cytokine regulation of the matrix metalloproteinases and their inhibitors in human papillomavirus-18 transformed human prostatic tumor cell lines.
Wang M; Fudge K; Rhim JS; Stearns ME
Oncol Res; 1996; 8(7-8):303-15. PubMed ID: 8938794
[TBL] [Abstract][Full Text] [Related]
39. Characterization of extracellular matrix-degrading proteinase and its inhibitor in gynecologic cancer tissues with clinically different metastatic form.
Tamakoshi K; Kikkawa F; Nawa A; Ishikawa H; Mizuno K; Tamakoshi A; Yamagata S; Suganuma N; Tomoda Y
Cancer; 1995 Dec; 76(12):2565-71. PubMed ID: 8625086
[TBL] [Abstract][Full Text] [Related]
40. Localization of messenger RNA for tissue inhibitor of metalloproteinases-1 and type IV collagenases/gelatinases in monkey hepatocellular carcinomas.
Lindsay CK; Thorgeirsson UP
Clin Exp Metastasis; 1995 Sep; 13(5):381-8. PubMed ID: 7641422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
